MX2020013182A - Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales. - Google Patents
Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.Info
- Publication number
- MX2020013182A MX2020013182A MX2020013182A MX2020013182A MX2020013182A MX 2020013182 A MX2020013182 A MX 2020013182A MX 2020013182 A MX2020013182 A MX 2020013182A MX 2020013182 A MX2020013182 A MX 2020013182A MX 2020013182 A MX2020013182 A MX 2020013182A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- acetylpyridin
- dione
- ethoxy
- disorder
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- JMLKLMFMQRAJNI-UHFFFAOYSA-N 5-[[4-[2-(5-acetylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC(C(=O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 JMLKLMFMQRAJNI-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000012268 mitochondrial disease Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract 1
- 201000005746 Pituitary adenoma Diseases 0.000 abstract 1
- 206010061538 Pituitary tumour benign Diseases 0.000 abstract 1
- 208000033781 Thyroid carcinoma Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000021310 pituitary gland adenoma Diseases 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382402 | 2018-06-06 | ||
| PCT/IB2019/054744 WO2019234690A1 (en) | 2018-06-06 | 2019-06-06 | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013182A true MX2020013182A (es) | 2021-02-26 |
Family
ID=62716011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013182A MX2020013182A (es) | 2018-06-06 | 2019-06-06 | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210228558A1 (enExample) |
| EP (1) | EP3801517A1 (enExample) |
| JP (1) | JP7510170B2 (enExample) |
| KR (1) | KR20210031867A (enExample) |
| CN (1) | CN112823004A (enExample) |
| AU (1) | AU2019283650A1 (enExample) |
| BR (1) | BR112020024939A2 (enExample) |
| CA (1) | CA3102584A1 (enExample) |
| CL (1) | CL2020003163A1 (enExample) |
| EA (1) | EA202092954A1 (enExample) |
| IL (1) | IL279186A (enExample) |
| MX (1) | MX2020013182A (enExample) |
| SG (1) | SG11202012095XA (enExample) |
| WO (1) | WO2019234690A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| MX2020013181A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| HUE071482T2 (hu) | 2018-06-06 | 2025-08-28 | Minoryx Therapeutics S L | (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra |
| CN116390725A (zh) * | 2020-04-30 | 2023-07-04 | 米尼奥尔克斯治疗有限公司 | 用于治疗肺部炎症和间质性肺病的羟基吡格列酮 |
| WO2022243435A1 (en) * | 2021-05-19 | 2022-11-24 | Abliva Ab | Kl1333 for use in medicine |
| WO2024231881A2 (en) * | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3579049B2 (ja) | 1992-04-30 | 2004-10-20 | インスティチュート・パスツール | Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓにおける抗生物質耐性の迅速検出法 |
| GB0030845D0 (en) * | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
| GB0510469D0 (en) * | 2005-05-23 | 2005-06-29 | Leuven K U Res & Dev | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth |
| AU2012203941A1 (en) * | 2006-06-27 | 2012-07-26 | Sandoz Ag | New method for salt preparation |
| EP2436381A1 (en) * | 2006-06-27 | 2012-04-04 | Sandoz AG | Crystallization of hydrohalides of pharmaceutical compounds |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| NZ725492A (en) | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| WO2017083739A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| CN110198945B (zh) | 2016-12-23 | 2023-06-27 | 米尼奥尔克斯治疗有限公司 | 用于制备噻唑烷二酮化合物及其盐的方法 |
-
2019
- 2019-06-06 MX MX2020013182A patent/MX2020013182A/es unknown
- 2019-06-06 AU AU2019283650A patent/AU2019283650A1/en not_active Abandoned
- 2019-06-06 SG SG11202012095XA patent/SG11202012095XA/en unknown
- 2019-06-06 EP EP19742913.7A patent/EP3801517A1/en active Pending
- 2019-06-06 CA CA3102584A patent/CA3102584A1/en active Pending
- 2019-06-06 KR KR1020207037942A patent/KR20210031867A/ko not_active Abandoned
- 2019-06-06 BR BR112020024939-4A patent/BR112020024939A2/pt not_active Application Discontinuation
- 2019-06-06 EA EA202092954A patent/EA202092954A1/ru unknown
- 2019-06-06 US US16/972,366 patent/US20210228558A1/en not_active Abandoned
- 2019-06-06 JP JP2020567972A patent/JP7510170B2/ja active Active
- 2019-06-06 WO PCT/IB2019/054744 patent/WO2019234690A1/en not_active Ceased
- 2019-06-06 CN CN201980046666.1A patent/CN112823004A/zh active Pending
-
2020
- 2020-12-03 IL IL279186A patent/IL279186A/en unknown
- 2020-12-04 CL CL2020003163A patent/CL2020003163A1/es unknown
-
2023
- 2023-09-01 US US18/460,197 patent/US20240091210A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3102584A1 (en) | 2019-12-12 |
| EA202092954A1 (ru) | 2021-04-08 |
| JP2021527061A (ja) | 2021-10-11 |
| SG11202012095XA (en) | 2021-01-28 |
| WO2019234690A1 (en) | 2019-12-12 |
| IL279186A (en) | 2021-01-31 |
| CL2020003163A1 (es) | 2021-07-02 |
| BR112020024939A2 (pt) | 2021-03-09 |
| AU2019283650A1 (en) | 2021-01-07 |
| US20240091210A1 (en) | 2024-03-21 |
| CN112823004A (zh) | 2021-05-18 |
| JP7510170B2 (ja) | 2024-07-03 |
| KR20210031867A (ko) | 2021-03-23 |
| EP3801517A1 (en) | 2021-04-14 |
| US20210228558A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092954A1 (ru) | Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей | |
| CY1124116T1 (el) | 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος | |
| PH12022551169A1 (en) | METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS | |
| MX2024001201A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con agonistas de glp-1 para usarse en tratar enfermedades del higado graso. | |
| HRP20211032T1 (hr) | Postupci za uporabu agonista fxr | |
| MA35156B1 (fr) | 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoléin-2-one destinée à être utilisée dans le traitement du carcinome adénoïde kystique | |
| MX374215B (es) | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| NZ602125A (en) | Uses of dgat1 inhibitors | |
| PH12018501903B1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| RU2016141055A (ru) | Препараты арипипразола, имеющие повышенные скорости впрыска | |
| MX2013009842A (es) | Composicion que comprende receptor gamma activado por proliferador de peroxisoma. | |
| EP4545142A3 (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases | |
| MX2020013181A (es) | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| JP2020500868A5 (enExample) | ||
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| WO2016046130A1 (en) | Methods and pharmaceutical compositions for the treatment of fibrosis | |
| MX2022013021A (es) | Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. | |
| Peroutka | Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache | |
| IL277332B1 (en) | Compositions and methods for treating severe constipation | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| MX2025002863A (es) | Alimentos y metodos para el control de infecciones por gusanos en el corazon en un mamifero | |
| Aydin | Peginterferon-α-2b | |
| PH12014501088A1 (en) | Pharmaceutical composition for preventing or treating hyperlipidemia |